The YODA Study, an acronym for Young-Onset Diabetes in sub-Saharan Africa.
By: Dr Paula Diab, PhD, CDCES Diabetologist & Weight Management Specialist
It’s not every day that diabetes research sounds like something out of Star Wars. But the YODA study – an acronym for Young-Onset Diabetes in sub-Saharan Africa—has certainly brought “new hope” to our understanding of type 1 diabetes.
And while this YODA doesn’t live in a galaxy far, far away, its message carries the same quiet wisdom: “Do. Or do not. There is no try.”
A landmark paper in The Lancet Diabetes & Endocrinology (Katte JC et al. Lancet Diabetes & Endocrinology. 2025; 13: 745–53.) reveals that not all young people diagnosed with type 1 diabetes (T1D) have the classic autoimmune form of the disease. In fact, researchers found a novel, non-autoimmune type of insulin-deficient diabetes that may also be present in some African Americans.
What the YODA study found
Researchers from the University of Exeter and partners across Africa examined nearly 900 young people from Cameroon, Uganda, and South Africa who had been clinically diagnosed with T1D. Surprisingly, only about 35% had autoimmune markers (islet autoantibodies)—a hallmark of classic T1D.
The remaining 65% were antibody-negative, meaning their diabetes was not caused by autoimmune destruction of insulin-producing cells. Despite this, they still had very low insulin levels, ruling out type 2 diabetes or malnutrition-related forms.
When the researchers compared their findings to U.S. data from the SEARCH for Diabetes in Youth study, they found a similar—though less frequent—pattern: about 15% of African American participants diagnosed with T1D were also autoantibody-negative, compared to only 9% of White participants.
What does this mean for patients and clinicians in the U.S.?
The results suggest that some individuals—particularly those of African ancestry—may have a form of non-autoimmune, insulin-deficient diabetes that looks like T1D but arises from a different biological pathway. This distinction matters because:
- Diagnosis: Autoantibody testing (GAD, IA-2, ZnT8) can help determine whether a person truly has autoimmune T1D. Those who test negative might benefit from additional genetic or C-peptide testing.
- Treatment: Both autoimmune and non-autoimmune insulin-deficient diabetes require insulin therapy, but understanding the cause could lead to personalized treatment strategies and help avoid misclassification as type 2 diabetes.
- Research and prevention: Identifying this new subtype may open the door to studying environmental, nutritional, or infectious triggers that contribute to β-cell failure outside of autoimmunity.
– Key takeaways for American patients and providers –
- Not all insulin-dependent diabetes in young people is autoimmune. Roughly 1 in 6 African Americans diagnosed with T1D may have a non-autoimmune form.
- Accurate classification matters. Testing for autoantibodies and C-peptide can clarify the diagnosis and guide therapy.
- Personalized care is essential. Ethnic background, family history, and clinical features should all inform diagnosis and management.
- Future therapies may differ. Understanding what causes β-cell failure in this non-autoimmune subtype could lead to new ways to preserve insulin production.
Why it matters
This discovery challenges the traditional “one-size-fits-all” understanding of T1D and highlights the need for inclusivity in diabetes research. Most of what we know about autoimmune diabetes has come from studies in people of European ancestry. The YODA study underscores the importance of studying diverse populations to improve outcomes for everyone living with diabetes.
At Integrated Diabetes Services, we believe that understanding these nuances empowers both patients and clinicians. If your child has been diagnosed with type 1 Diabetes or you have been diagnosed with Type 1 Diabetes, especially if the diagnosis doesn’t quite “fit,” ask your care team about antibody and C-peptide testing.
Knowledge is power—and precision is progress. (And as Yoda might say, “Much to learn, we still have.”)
Reference: Katte JC et al. Lancet Diabetes & Endocrinology. 2025; 13: 745–53.
Study Title: Non-autoimmune, insulin-deficient diabetes in children and young adults in Africa: evidence from the Young-Onset Diabetes in sub-Saharan Africa (YODA) study.
